COVID-19：Kaneka提供PCR试剂：Kaneka Eurogentec /首批200,000瓶
COVID-19：Kaneka
在比利时和邻国，Kaneka集团公司Kaneka Eurogentec将提高PCR试剂的生产。
应比利时政府的要求，PCR检测试剂可用于新的冠状病毒检测。
开始首次向比利时/邻国的医院/实验室/研究机构提供200,000当量/ PCR测试试剂。
比利时：那慕尔大学
成功开发出一种简单的检测方法（不使用特定于设备的专用试剂）。
比利时联邦医疗和保健产品局批准将其作为一种新的冠状病毒检测方法。
对于该测试，采用了Kaneka Eurogentec的PCR测试试剂（Takyon）。
这是比利时当局的供应要求。
Kaneka Eurogentec：
预期将其应用于疫苗和治疗剂。
我们拥有用于高质量信使RNA（mRNA）和质粒DNA的世界一流技术。
食品行业新闻WEB
https://www.ssnp.co.jp/news/soy/2020/04/2020-0408-1350-16.html
Kaneka Eurogentec begins supplying reagents for novel coronavirus testing Kaneka Corporation
April 2, 2020
Kaneka Eurogentec S.A. (Headquarters: Liège, Belgium; President: Lieven Janssens), an affiliate of Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka),
has reinforced production of PCR*1 reagents used in the novel coronavirus testing, as per requested by the Belgian government.
They have begun supplying hospitals, testing organizations and research institutes in Belgium and its neighboring countries with enough PCR reagents to conduct around 200,000 tests for the first shipment.
University of Namur (Namur, Belgium)
has succeeded in developing a convenient detection method that refrains from using reagents that require specialized equipment,
this was approved as a method for the novel coronavirus testing by Belgium’s Federal Agency for Medicines and Health Products.
The method
uses Kaneka Eurogentec’s PCR reagent (TakyonTM), which led to the request from the Belgian authorities to supply the reagent.
Kaneka Eurogentec S.A.
also possesses world-leading technologies for high quality mRNA*2 and plasmid DNA*3.
They have strengthened GMP*4 manufacturing of mRNA and plasmid DNA in order to respond to growing inquiries on a novel coronavirus vaccine, which pharmaceutical companies and biotech ventures are accelerating development of.
Kaneka will put in every effort to provide solutions to the novel coronavirus for worldwide health.